Danish biotechnology company MinervaX has announced a collaboration with Wacker Biotech, a subsidiary of Wacker Chemie (ETR: WCH), to manufacture active protein ingredients.
The agreement relates to the firm’s novel vaccine against Group B Streptococcus (GBS), a cause of life-threatening infections for which there are currently no fully protective treatments.
GBS is a significant cause of dangerous infections in newborns, responsible for nearly half of such cases. The condition can lead to severe outcomes, including long-term disability or death.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze